Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
NASDAQ:PSTV
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$0.16 - $2.31
Previous CloseN/A
Volume69.06K
Average Volume (3M)14.29M
Market Cap
$45.31M
Enterprise Value$2.47M
Total Cash (Recent Filing)$13.29M
Total Debt (Recent Filing)$21.00K
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Feb 19, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding178,371,230
10 Day Avg. Volume13,255,022
30 Day Avg. Volume14,285,731
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.85
Price to Sales (P/S)1.31
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.47
Enterprise Value/Gross Profit0.53
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$5.88Price Target Upside913.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Utility EvidenceThe FORESEE study showed CNSide results influenced treatment decisions in 90% of cases, reinforcing the test's clinical value in managing leptomeningeal disease and encouraging physician uptake.
Regulatory PathwayFDA feedback endorses an accelerated approval pathway for the leptomeningeal metastases program and aligns on a pivotal trial design for Reyobiq, increasing the likelihood of a streamlined registration path.
Reimbursement And Payer CoverageNational coverage agreements with UnitedHealthcare and Humana expand CNSide payer coverage to 67 million covered lives, enhancing reimbursement prospects and supporting broader clinical adoption.
Bears Say
Clinical And Development RiskOngoing clinical trial uncertainties and the risk of adverse or inconclusive pivotal study outcomes remain significant valuation challenges that could weaken investor confidence.
Commercial Rollout And LicensingCNSide's launch is concentrated in Texas while licensing and regulatory approvals are pursued in other states, which could slow revenue growth and delay nationwide commercialization.
Financing And DilutionA public equity offering increased dilution and prompted analysts to lower the price target, creating downside pressure for existing shareholders despite an extended cash runway.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $45.31M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 7 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Oct 30, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.02.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 178,371,230 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went up 2.453%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (913.79% Upside)
$5.88 (913.79% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
167.56%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Stock 12 Month Forecast
Average Price Target
$5.88
▲(913.79% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.49% Insiders
0.76% Mutual Funds
0.02% Other Institutional Investors
97.99% Public Companies and Individual Investors
Options Prices
Currently, No data available
---